SOHO ANNUAL MEETING 2024

CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRANODAL NK T-CELL LYMPHOMA NASAL TYPE (ENKTL): A DECADE'S EXPERIENCE

D. Podder[1] MBBS, MD, DM, PDF, S. Bhattacharyya[1] MD, R. Pincha[2] MD, DrNB, A. Sahoo[1] MD, Baalamurugan KT[1] MD, S. Shinde[1] DNB, P. Mundra[1] MD, D. Chattopadhyay[1] MD, DM, DrNB, S. Ghosh[1] MD, DM, A. Nag[1] MD, DM, J. Kumar[1] MD, DrNB, L. Zameer[3] MD, I. Arun[3] MD, R. Achari[4] MD, R. Nair[1] MD

1. Dept of Clinical Hematology and Cellular Therapies Tata Medical Center, Kolkata, India 2. Dept of Hematology, Apollo Hospital, Guwahati 3. Dept of Histopathology, Tata Medical C enter 4. Dept of R adiation Oncology, Tata Medical Center

TATA MEDICAL CENTER

INTRODUCTION

• Extranodal NK/T-cell lymphoma (ENKTL), nasal type, is a rare type of non-Hodgkin lymphoma

•Commonly seen in East Asian countries and associated with EBV infection.

•Presents as a nasal mass with a locally aggressive lesion with bony destruction.

OBJECTIVE

Primary Objective:

Describe the clinical characteristics of patients with ENKTL

Secondary :

Analyze (OS), event-free survival (EFS), and evaluate toxicities after first-line treatment.

METHOD


- Retrospective analysis from 2012 to 2024
- All demographic data, clinical symptoms, staging workup, and chemotherapy records were collected from electronic medical records.
- Adverse events were graded as per CTCAE v5.0.
- Kaplan-Meier curves were used to determine OS and EFS.
- SPSS v29 was used for all statistical analysis.


RESULTS

- 27 patients were included in the study
- Median age was 44 years (range, 31-75 years).
- Male preponderance was seen (M:F=2:1)
- 70% of the patients were from Bhutan.
- L-asparaginase-based regimen with upfront radiotherapy was used in 70% of the patients
- Grade 3/4 neutropenia and thrombocytopenia were seen in 52% and 41%, respectively.
- 11.1% of the patients died of regimen-related toxicity.
- 10-year OS was 56% and the median EFS was 10.5 yrs

Baseline characteristics			N= 27 (%)
Age			44 (31-75 yrs)
Gender	Male		18 (66%)
	Female		9 (33%)
Symptoms	Nasal blockade		21 (77.7%)
	Dysphagia		7 (25.9%)
	Facial swelling		4 (14.8%)
	Headache		4 (14.8%)
	Blurring vision		2 (7.4%)
	Testicular swelling		1 (3.7%)
	Eye watering		1 (3.7%)
	B symptoms		2 (7.4%)
Primary site	Nasal		23 (85.18%)
	Extranasal	Testes	2 (7.4%)
		Skin	1 (3.7%)
		Spleen	1 (3.7%)
Stage	I		10 (37%)
	II		6 (22.2%)
	IV		11 (40.7%)
Pink (Prognostic index of NK/T cell lymphoma)	Low		13 (48.1%)
	Intermediate		10 (37%)
	High		3 (11.1%)

TREATMENT, OUTCOME, TOXICITIES		N= 27 (%)	
1st Line treatment	SMILE	16 (59.3)	
	CHOP	4 (14.8%)	
	Aspa-Met-Dex	3 (11.1%)	
	CHOEP	1 (3.7%)	
	Best Supportive Care	2 (7.4%)	
Radiotherapy	Yes	9 (33.3%)	
	No	18 (66.6%)	
Response rate	Complete Response	16 (59.3%)	
	Progressive Disease	5 (22.2%)	
	Not assessed	6	
Toxicities		Grade 1/2	Grade >3
	Mucositis	5 (18.5%)	-
	Neutropenia	2 (7.4%)	14 (51.8%)
	Thrombocytopenia	2 (7.4%)	11 (40.7)
	Liver dysfunction	10 (37%)	6 (22.2%)
	Pancreatitis	2 (7.4%)	-
	Blood Stream Infection	7 (25.9%)	
	Ifosfamide Encephalopathy	2 (7.4%)	-
Death		3 (11.1%)	





CONCLUSIONS

•Extranodal NK/T-cell lymphoma (ENKTL), nasal type, is a rare type of non-Hodgkin lymphoma

•Predominantly seen in East Asian populations

•Present predominantly as limited stage disease with intranasal mass and nasal obstruction.

• Has an excellent OS and EFS when treated with asparaginase-based regimen

•Toxicity profile is manageable.

REFERENCES

- Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood 2013;121:4997-5005.
- Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood 2018;131:2528-40.
- Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011;29:4410-6.
- Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012;120:2973-80.
- Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011;117:1834-9.

CONTACT INFORMATION

Dr Dibakar Podder

drdibakarpodder@gmail.com

dibakar.podder@tmckolkata.com

+919436523404

Prof Reena Nair

reena.nair@tmckolkata.com